Michele Fabrazzo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2505414/publications.pdf

Version: 2024-02-01

52 1,665 23
papers citations h-index

40 g-index

289244

53 all docs

53 docs citations 53 times ranked 2004 citing authors

#	Article	IF	CITATIONS
1	Internetâ€based field trials of the <scp>ICD</scp> â€11 chapter on mental disorders. World Psychiatry, 2022, 21, 163-164.	10.4	2
2	A Multivariate Analysis of Depression Prevalence in Psoriasis Patients: A Cohort Study. International Journal of Environmental Research and Public Health, 2022, 19, 2060.	2.6	2
3	Delirium and Psychiatric Sequelae Associated to SARS-CoV-2 in Asymptomatic Patients With Psychiatric History and Mild Cognitive Impairment as Risk Factors: Three Case Reports. Frontiers in Psychiatry, 2022, 13, 868286.	2.6	1
4	Social Cognition Individualized Activities Lab for Social Cognition Training and Narrative Enhancement in Patients With Schizophrenia: A Randomized Controlled Study to Assess Efficacy and Generalization to Real-Life Functioning (Prot. n°: NCT05130853). Frontiers in Psychiatry, 2022, 13, 833550.	2.6	2
5	Investigating the Relationship between White Matter Connectivity and Motivational Circuits in Subjects with Deficit Schizophrenia: A Diffusion Tensor Imaging (DTI) Study. Journal of Clinical Medicine, 2022, 11, 61.	2.4	10
6	A hypothesis on Cotard's syndrome as an evolution of obsessive-compulsive disorder. International Review of Psychiatry, 2021, 33, 23-28.	2.8	0
7	Duration of untreated illness predicts 3-year outcome in patients with obsessive-compulsive disorder: A real-world, naturalistic, follow-up study. Psychiatry Research, 2021, 299, 113872.	3.3	20
8	Bipolar Patients and Bullous Pemphigoid after Risperidone Long-Acting Injectable: A Case Report and a Review of the Literature. Brain Sciences, $2021,11,1386.$	2.3	3
9	A systematic review on shared biological mechanisms of depression and anxiety in comorbidity with psoriasis, atopic dermatitis, and hidradenitis suppurativa. European Psychiatry, 2021, 64, e71.	0.2	20
10	Delirium and Cognitive Impairment as Predisposing Factors of COVID-19 Infection in Neuropsychiatric Patients: A Narrative Review. Medicina (Lithuania), 2021, 57, 1244.	2.0	8
11	Did we learn something positive out of the COVID-19 pandemic? Post-traumatic growth and mental health in the general population. European Psychiatry, 2021, 64, 1-27.	0.2	22
12	Mismatch Negativity and P3a Impairment through Different Phases of Schizophrenia and Their Association with Real-Life Functioning. Journal of Clinical Medicine, 2021, 10, 5838.	2.4	8
13	Effects of Direct-Acting Antiviral Agents on the Mental Health of Patients with Chronic Hepatitis C: A Prospective Observational Study. Brain Sciences, 2020, 10, 483.	2.3	12
14	Klinefelter Syndrome: From a Disabling Condition to a Variant of Normalcy: Neuropsychiatric Aspects. Trends in Andrology and Sexual Medicine, 2020, , 77-83.	0.1	0
15	Comorbidity of Obsessive-Compulsive Disorder and Schizotypal Personality Disorder: Clinical Response and Treatment Resistance to Pharmacotherapy in a 3-Year Follow-Up Naturalistic Study. Frontiers in Psychiatry, 2019, 10, 386.	2.6	18
16	The unmasking of hidden severe hyponatremia after long-term combination therapy in exacerbated bipolar patients. International Clinical Psychopharmacology, 2019, 34, 206-210.	1.7	7
17	Impaired glucose metabolism in bipolar patients and response to mood stabilizer treatments. Journal of Affective Disorders, 2019, 245, 174-179.	4.1	31
18	Brain Natriuretic Peptide as a Biomarker of Asymptomatic Clozapine-Related Heart Dysfunction: A Criterion for a More Cautious Administration. Clinical Schizophrenia and Related Psychoses, 2019, 12, 185-188.	1.4	5

#	Article	IF	CITATIONS
19	Social versus biological psychiatry: It's time for integration!. International Journal of Social Psychiatry, 2018, 64, 617-621.	3.1	11
20	How to improve clinical practice on forced medication in psychiatric practice: Suggestions from the EUNOMIA European multicentre study. European Psychiatry, 2018, 54, 35-40.	0.2	20
21	Clozapine versus other antipsychotics during the first 18 weeks of treatment: A retrospective study on risk factor increase of blood dyscrasias. Psychiatry Research, 2017, 256, 275-282.	3.3	25
22	Campania Region (Italy) spontaneous reporting system and preventability assessment through a case-by-case approach: a pilot study on psychotropic drugs. Expert Opinion on Drug Safety, 2016, 15, 9-15.	2.4	36
23	Leucocytosis in clozapine-treated patients as predictor of loss of treatment response?. BMJ Case Reports, 2015, 2015, bcr2014209148-bcr2014209148.	0.5	2
24	Olanzapine Is Faster than Haloperidol in Inducing Metabolic Abnormalities in Schizophrenic and Bipolar Patients. Neuropsychobiology, 2015, 72, 29-36.	1.9	20
25	From over- to under-weight: treatment of post-surgical anorexia nervosa in morbid obesity. Eating and Weight Disorders, 2015, 20, 529-532.	2.5	4
26	Central and Peripheral Peptides Regulating Eating Behaviour and Energy Homeostasis in Anorexia Nervosa and Bulimia Nervosa: A Literature Review. European Eating Disorders Review, 2014, 22, 307-320.	4.1	40
27	Flattened cortisol awakening response in chronic patients with schizophrenia onset after cannabis exposure. Psychiatry Research, 2014, 215, 263-267.	3.3	23
28	Add-on oral olanzapine worsens hallucinations in schizoaffective disorder. BMJ Case Reports, 2014, 2014, bcr2014205805-bcr2014205805.	0.5	3
29	Aripiprazole augmentation strategy in clomipramine-resistant depressive patients: An open preliminary study. European Neuropsychopharmacology, 2012, 22, 132-136.	0.7	11
30	Obsessive–compulsive disorder with poor insight: A three-year prospective study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 323-330.	4.8	161
31	Depression in Chronic Kidney Disease. Seminars in Nephrology, 2006, 26, 56-60.	1.6	39
32	Circulating ghrelin is decreased in non-obese and obese women with binge eating disorder as well as in obese non-binge eating women, but not in patients with bulimia nervosa. Psychoneuroendocrinology, 2005, 30, 243-250.	2.7	77
33	Plasma Leptin and Antipsychotic-Induced Body Weight Gain. Neuropsychopharmacology, 2005, 30, 1769-1769.	5.4	2
34	Circulating brain-derived neurotrophic factor is decreased in women with anorexia and bulimia nervosa but not in women with binge-eating disorder: relationships to co-morbid depression, psychopathology and hormonal variables. Psychological Medicine, 2005, 35, 897-905.	4.5	99
35	Investigation of peptide YY and ghrelin responses to a test meal in bulimia nervosa. Biological Psychiatry, 2005, 57, 926-931.	1.3	74
36	Long-Term Treatment With Clozapine Does Not Affect Morning Circulating Levels of Allopregnanolone and THDOC in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2004, 24, 437-440.	1.4	9

#	Article	IF	CITATIONS
37	Opposite Changes in Circulating Adiponectin in Women With Bulimia Nervosa or Binge Eating Disorder. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5387-5391.	3.6	42
38	Ghrelin and leptin responses to food ingestion in bulimia nervosa: implications for binge-eating and compensatory behaviours. Psychological Medicine, 2003, 33, 1387-1394.	4.5	73
39	Pronounced Early Increase in Circulating Leptin Predicts a Lower Weight Gain During Clozapine Treatment. Journal of Clinical Psychopharmacology, 2002, 22, 424-426.	1.4	60
40	Is the Time Course of Clozapine Response Correlated to the Time Course of Clozapine Plasma Levels? A One-Year Prospective Study in Drug-Resistant Patients with Schizophrenia. Neuropsychopharmacology, 2002, 27, 1050-1055.	5 . 4	48
41	Opposite modifications in circulating leptin and soluble leptin receptor across the eating disorder spectrum. Molecular Psychiatry, 2002, 7, 641-646.	7.9	79
42	Plasma Concentrations of Amino Acids in Chronic Schizophrenics Treated with Clozapine. Neuropsychobiology, 2001, 44, 167-171.	1.9	63
43	Plasma Leptin Response to Acute Fasting and Refeeding in Untreated Women with Bulimia Nervosa. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2499-2503.	3.6	47
44	Fluvoxamine Increases Plasma and Urinary Levels of Clozapine and Its Major Metabolites in a Time- and Dose-Dependent Manner. Journal of Clinical Psychopharmacology, 2000, 20, 708-710.	1.4	27
45	Plasma Leptin Response to Acute Fasting and Refeeding in Untreated Women with Bulimia Nervosa. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2499-2503.	3.6	10
46	Immunoendocrine Findings in Patients with Eating Disorders. Neuropsychobiology, 1999, 40, 115-120.	1.9	38
47	Decreased Blood Levels of Tumor Necrosis Factor-Alpha in Patients with Obsessive-Compulsive Disorder. Neuropsychobiology, 1998, 37, 182-185.	1.9	59
48	Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. International Clinical Psychopharmacology, 1998, 13, 141.	1.7	70
49	Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Research, 1997, 71, 11-17.	3. 3	130
50	Induction of nerve growth factor and basic fibroblast growth factor mRNA following clenbuterol: Contrasting anatomical and cellular localization. Experimental Neurology, 1995, 132, 33-41.	4.1	43
51	Chronic treatment with scopolamine and physostigmine changes nerve growth factor (NGF) receptor density and NGF content in rat brain. Brain Research, 1991, 542, 233-240.	2.2	26
52	Regulation of nerve growth factor receptor mRNA content by dexamethasone: In vitro and in vivo studies. Neuroscience Letters, 1990, 116, 216-220.	2.1	19